[
  {
    "ts": "2026-01-12T01:31:34+00:00",
    "headline": "Eli Lilly Study Finds Zepbound Dual Treatment Improves Arthritis, Helps Patients Lose Weight",
    "summary": "On Thursday, Eli Lilly and Co. (NYSE:LLY) revealed topline results from the novel TOGETHER-PsA open-label Phase 3b trial evaluating the concomitant use of Taltz (ixekizumab) and Zepbound (tirzepatide) compared to Taltz alone for active psoriatic arthritis (PsA) and obesity or overweight with at least one weight-related condition. Psoriatic arthritis is linked to psoriasis (a condition that affects skin and nails). It causes joint pain, stiffness, and a skin rash. At 36 weeks, treatment with conc",
    "url": "https://finance.yahoo.com/news/eli-lilly-study-finds-zepbound-013134669.html",
    "source": "Benzinga",
    "provider": "yfinance",
    "raw": {
      "id": "decdd05a-2eb3-3f12-8f69-a129cf31f570",
      "content": {
        "id": "decdd05a-2eb3-3f12-8f69-a129cf31f570",
        "contentType": "STORY",
        "title": "Eli Lilly Study Finds Zepbound Dual Treatment Improves Arthritis, Helps Patients Lose Weight",
        "description": "",
        "summary": "On Thursday, Eli Lilly and Co. (NYSE:LLY) revealed topline results from the novel TOGETHER-PsA open-label Phase 3b trial evaluating the concomitant use of Taltz (ixekizumab) and Zepbound (tirzepatide) compared to Taltz alone for active psoriatic arthritis (PsA) and obesity or overweight with at least one weight-related condition. Psoriatic arthritis is linked to psoriasis (a condition that affects skin and nails). It causes joint pain, stiffness, and a skin rash. At 36 weeks, treatment with conc",
        "pubDate": "2026-01-12T01:31:34Z",
        "displayTime": "2026-01-12T01:31:34Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Benzinga/ebc5670b38d99be85ea6a2f16ff0bb54",
          "originalWidth": 1000,
          "originalHeight": 666,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/0iWz1yDq.CSuFi.9R45_Dw--~B/aD02NjY7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Benzinga/ebc5670b38d99be85ea6a2f16ff0bb54.cf.webp",
              "width": 1000,
              "height": 666,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/lSgReJnkqZecsqPPZ7zBjA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/ebc5670b38d99be85ea6a2f16ff0bb54.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Benzinga",
          "url": "http://www.benzinga.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-study-finds-zepbound-013134669.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-study-finds-zepbound-013134669.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]